Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Change in Interest Receivables (2023 - 2025)

Historic Change in Interest Receivables for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $1.5 million.

  • Nuvation Bio's Change in Interest Receivables rose 52979.59% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 2549.73%. This contributed to the annual value of -$132000.0 for FY2024, which is 11084.63% down from last year.
  • Latest data reveals that Nuvation Bio reported Change in Interest Receivables of $1.5 million as of Q3 2025, which was up 52979.59% from -$1.1 million recorded in Q2 2025.
  • Nuvation Bio's 5-year Change in Interest Receivables high stood at $1.5 million for Q3 2025, and its period low was -$1.1 million during Q2 2025.
  • For the 3-year period, Nuvation Bio's Change in Interest Receivables averaged around $276545.5, with its median value being $245000.0 (2024).
  • As far as peak fluctuations go, Nuvation Bio's Change in Interest Receivables tumbled by 18505.23% in 2024, and later surged by 52979.59% in 2025.
  • Over the past 3 years, Nuvation Bio's Change in Interest Receivables (Quarter) stood at $669000.0 in 2023, then plummeted by 185.05% to -$569000.0 in 2024, then soared by 371.18% to $1.5 million in 2025.
  • Its Change in Interest Receivables was $1.5 million in Q3 2025, compared to -$1.1 million in Q2 2025 and $1.5 million in Q1 2025.